Clinical Research Directory
Browse clinical research sites, groups, and studies.
Mechanisms for Activation of Beige Adipose Tissue in Humans
Sponsor: Philip Kern
Summary
Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance and adipose tissue in prediabetic patients
Key Details
Gender
All
Age Range
35 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
65
Start Date
2020-12-07
Completion Date
2026-12-01
Last Updated
2026-02-03
Healthy Volunteers
Yes
Conditions
Interventions
Placebo
Participants will take one pill (placebo) daily for the first week and two pills daily for the remaining 15 weeks.
Mirabegron
Participants will take one pill (50mg Mirabegron) daily for the first week. For week two, participants will take two pills (50mg and 25mg Mirabegron). Unless there are side effects, for the remaining 14 weeks participants will take two pills (50mg each) daily.
Mirabegron 50 MG
Participants will take one pill (50mg Mirabegron) daily between visit 2 and visit 3
Mirabegron 100 mg
participants will be given 6 weeks of mirabegron (25 mg) and will take 1 pill once per day for 4-6 weeks. Next participants will be given 6 weeks of mirabegron (50 mg) and take 1 pill once per day for 4-6 weeks. Last participants will be given 6 weeks of mirabegron (100 mg) and take 1 pill once per day for 4-6 weeks.
Locations (1)
University of Kentucky
Lexington, Kentucky, United States